Targeting MYC through WDR5

Lance R Thomas1, Clare M Adams2, Stephen W Fesik3

  • 1Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN, USA.

Insights

The MYC oncoprotein drives cancer but is hard to drug. Disrupting MYC

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • The MYC oncoprotein is overexpressed in many cancers, leading to significant mortality.
  • MYC is a validated anti-cancer target, yet remains undruggable with current therapies.

Purpose of the Study:

  • To investigate the therapeutic potential of inhibiting the MYC oncoprotein.
  • To explore the disruption of the MYC-WD repeat-containing protein 5 (WDR5) interaction as a novel anti-cancer strategy.

Main Methods:

  • Utilized mouse xenograft models to study tumor regression.
  • Focused on breaking the interaction between MYC and its chromatin co-factor WDR5.

Main Results:

  • Disrupting the MYC-WDR5 interaction led to significant tumor regression in preclinical models.
  • This approach provides a new avenue for MYC inhibition.

Conclusions:

  • Targeting the MYC-WDR5 interaction is a promising strategy for cancer therapy.
  • This research lays the groundwork for clinical development of MYC-targeted treatments.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
10.2K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
5.2K
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K